David Bouhadana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
David Bouhadana has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
- David-Dan Nguyen
Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada
6 shared publications - Naeem Bhojani
Division of Urology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Canada
6 shared publications - Dean Elterman
Division of Urology, Department of Surgery, University of Toronto, Toronto, Canada
5 shared publications - Iman Sadri
Division of Urology, McGill University, Montreal, Canada
5 shared publications - Bilal Chughtai
Department of Urology, Northwell Health, Syosset, NY 11791, USA
4 shared publications - Carlos Vasquez-Lastra
Department of Urology, ABC Medical Center, Mexico City, Mexico
4 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by Wiley in BJU International
- Vol. 138 (6) , 1171-1179
Aquablation as salvage therapy for benign prostatic hyperplasia: an international multicentre study
Objective: Our objective was to evaluate the safety and effectiveness of Aquablation® as a salvage therapy in patients who underwent prior intervention for benign prostatic hyperplasia (BPH). Materials and Methods: We retrospectively analysed 1887 consecutive men from the International Collaborative Aquablation Research Urology Society database between 2018 and 2024 who underwent Aquablation at one of four international centres. The cohort was divided into two groups based on the presence or absence of previous BPH intervention. Baseline characteristics, clinical and functional outcomes, and complication rates were compared between the two groups using analysis of variance and Kruskal–Wallis tests. Finally, exploratory sub‐analyses were performed in the salvage therapy group based on the type of prior BPH intervention. Results: Among the study population of 1887 men, 109 (5.8%) patients had undergone prior BPH intervention, and the remaining 1778 (94.2%) patients served as a control cohort. Prostate volumes were similar between both groups (82.3 vs 78.0 mL; P = 0.18). There were no significant differences in perioperative complications, 30‐day readmission rates, surgical retreatment rates, or sexual function outcome scores (all P > 0.05). There were also similar improvements in maximum urinary flow rates, post‐void residuals, International Prostate Symptom Scores, and quality of life scores (all P > 0.05). When comparing outcomes based on the type of prior BPH intervention, there were no differences in terms of operative time, prostate volumes, presence of median lobe, or complication rates. Conclusion: We observed no statistically significant differences in safety or effectiveness for Aquablation as a salvage therapy for recurrent lower urinary tract symptoms after BPH intervention. Aquablation should be offered to men for whom prior procedures have failed and who want to preserve continence and sexual function.
- 7 October 2026
- Published by Wiley in BJU International
- Vol. 138 (6) , 1171-1179
Open AccessAquablation as salvage therapy for benign prostatic hyperplasia: an international multicentre study
Objective: Our objective was to evaluate the safety and effectiveness of Aquablation® as a salvage therapy in patients who underwent prior intervention for benign prostatic hyperplasia (BPH). Materials and Methods: We retrospectively analysed 1887 consecutive men from the International Collaborative Aquablation Research Urology Society database between 2018 and 2024 who underwent Aquablation at one of four international centres. The cohort was divided into two groups based on the presence or absence of previous BPH intervention. Baseline characteristics, clinical and functional outcomes, and complication rates were compared between the two groups using analysis of variance and Kruskal–Wallis tests. Finally, exploratory sub‐analyses were performed in the salvage therapy group based on the type of prior BPH intervention. Results: Among the study population of 1887 men, 109 (5.8%) patients had undergone prior BPH intervention, and the remaining 1778 (94.2%) patients served as a control cohort. Prostate volumes were similar between both groups (82.3 vs 78.0 mL; P = 0.18). There were no significant differences in perioperative complications, 30‐day readmission rates, surgical retreatment rates, or sexual function outcome scores (all P > 0.05). There were also similar improvements in maximum urinary flow rates, post‐void residuals, International Prostate Symptom Scores, and quality of life scores (all P > 0.05). When comparing outcomes based on the type of prior BPH intervention, there were no differences in terms of operative time, prostate volumes, presence of median lobe, or complication rates. Conclusion: We observed no statistically significant differences in safety or effectiveness for Aquablation as a salvage therapy for recurrent lower urinary tract symptoms after BPH intervention. Aquablation should be offered to men for whom prior procedures have failed and who want to preserve continence and sexual function.
- Open Access
- 30 January 2026
- Published by Wiley in BJUI Compass
- Vol. 7 (2)
Outcomes of Aquablation in BPH with bladder stones: Analysis of the ICARUS database
Objective: The purpose of this study is investigate the clinical outcomes of men with benign prostatic hyperplasia (BPH) and bladder stones treated concomitantly with Aquablation and bladder stone removal in an international, multi‐institutional cohort. Patients and Methods: We performed a retrospective analysis of men who underwent Aquablation between 2018 and 2024. Patients were divided into two cohorts: men with bladder stones and those without. Outcomes assessed included baseline demographics and variables (medication use, prostate volume, prior BPH surgery), operative characteristics (OR time, transfusion requirement, complications), and functional outcomes were measured by the International Prostate Symptom Score (IPSS), peak urinary flow rate ( Q max ) and PVR at regular intervals over 24 months. Results: A total of 1885 men were analysed, including 60 men with bladder stones and 1825 without. Patients with bladder stones had higher rates of prior BPH surgery (15% vs. 5.5%, p = 0.015) and pre‐operative urinary retention (28.3% vs. 14.8%, p = 0.004) as well as larger prostate volumes (98.6 ml vs. 77 ml, p < 0.0001). Total operative time was longer in the bladder stone group (76.5 mins vs. 55.0 mins, p < 0.001), but there were no significant differences in Aquablation time or bleeding complications including transfusions. There was also no difference in improvements in IPSS, Q max and PVR post‐operatively. Conclusion: This study demonstrates that Aquablation is safe and effective in the management of BPH regardless of concomitant bladder stone treatment.
- 30 January 2026
- Published by Wiley in BJUI Compass
- Vol. 7 (2)
Open AccessOutcomes of Aquablation in BPH with bladder stones: Analysis of the ICARUS database
Objective: The purpose of this study is investigate the clinical outcomes of men with benign prostatic hyperplasia (BPH) and bladder stones treated concomitantly with Aquablation and bladder stone removal in an international, multi‐institutional cohort. Patients and Methods: We performed a retrospective analysis of men who underwent Aquablation between 2018 and 2024. Patients were divided into two cohorts: men with bladder stones and those without. Outcomes assessed included baseline demographics and variables (medication use, prostate volume, prior BPH surgery), operative characteristics (OR time, transfusion requirement, complications), and functional outcomes were measured by the International Prostate Symptom Score (IPSS), peak urinary flow rate ( Q max ) and PVR at regular intervals over 24 months. Results: A total of 1885 men were analysed, including 60 men with bladder stones and 1825 without. Patients with bladder stones had higher rates of prior BPH surgery (15% vs. 5.5%, p = 0.015) and pre‐operative urinary retention (28.3% vs. 14.8%, p = 0.004) as well as larger prostate volumes (98.6 ml vs. 77 ml, p < 0.0001). Total operative time was longer in the bladder stone group (76.5 mins vs. 55.0 mins, p < 0.001), but there were no significant differences in Aquablation time or bleeding complications including transfusions. There was also no difference in improvements in IPSS, Q max and PVR post‐operatively. Conclusion: This study demonstrates that Aquablation is safe and effective in the management of BPH regardless of concomitant bladder stone treatment.
- 29 October 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-20
Large language model chatbots for patient education in kidney stones: a scoping review
Purpose In 2024, 17% of adults reported using an artificial intelligence (AI) chatbot at least once a month as a source of health information, rising to 25% among those under 30. We aim to conduct a scoping review of the existing literature assessing the performance of large language model (LLM) chatbots for patient education in kidney stone disease (KSD). Methods The Joanna Briggs Institute methodology was followed. Ovid MEDLINE, Embase, CENTRAL, Web of Science, CINAHL, and Google Scholar were searched for studies in all languages, from 2015 up to February 16th 2025, evaluating LLM chatbots to create educational content on KSD. Two independent reviewers completed screening, full-text review, and data extraction, with conflicts resolved by a third reviewer. Results Of the 281 search results, 17 were included. Five of six studies assessing readability found that LLM responses exceeded the recommended 6th-8th grade reading level, though effective prompting can help meet this target. Six out of eight studies reported adequate to very good accuracy performance, with two showing comparable performance to traditional information sources. Understandability and actionability performance was poor. Quality performance was variable across seven studies. Three studies assessed patients’ perception, revealing a mixed but generally favorable experience. Two studies noted notable deviations from established clinical guidelines. Conclusion LLM chatbots show potential for KSD patient education and physician workload reduction, but currently have limitations in readability, guideline adherence, understandability, and actionability. This could be mitigated by prompting and the development of urology-specific tools trained on validated content and evaluated with patient involvement.
- 29 October 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-20
Large language model chatbots for patient education in kidney stones: a scoping review
Purpose In 2024, 17% of adults reported using an artificial intelligence (AI) chatbot at least once a month as a source of health information, rising to 25% among those under 30. We aim to conduct a scoping review of the existing literature assessing the performance of large language model (LLM) chatbots for patient education in kidney stone disease (KSD). Methods The Joanna Briggs Institute methodology was followed. Ovid MEDLINE, Embase, CENTRAL, Web of Science, CINAHL, and Google Scholar were searched for studies in all languages, from 2015 up to February 16th 2025, evaluating LLM chatbots to create educational content on KSD. Two independent reviewers completed screening, full-text review, and data extraction, with conflicts resolved by a third reviewer. Results Of the 281 search results, 17 were included. Five of six studies assessing readability found that LLM responses exceeded the recommended 6th-8th grade reading level, though effective prompting can help meet this target. Six out of eight studies reported adequate to very good accuracy performance, with two showing comparable performance to traditional information sources. Understandability and actionability performance was poor. Quality performance was variable across seven studies. Three studies assessed patients’ perception, revealing a mixed but generally favorable experience. Two studies noted notable deviations from established clinical guidelines. Conclusion LLM chatbots show potential for KSD patient education and physician workload reduction, but currently have limitations in readability, guideline adherence, understandability, and actionability. This could be mitigated by prompting and the development of urology-specific tools trained on validated content and evaluated with patient involvement.
- Top Cited PapersOpen Access
- 19 August 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (8) , 1013
The Role of Antioxidants in Male Fertility: A Comprehensive Review of Mechanisms and Clinical Applications
Oxidative stress is a significant factor in male infertility, with increasing evidence evaluating the role of antioxidants in mitigating its detrimental effects on sperm function and quality. This review examines the mechanisms by which reactive oxygen species (ROS) impact male reproductive health. This article synthesizes the different mechanisms at play and highlights key clinical studies published in the literature that contribute to our understanding of antioxidants to treat male infertility. These studies suggest that supplementation with specific antioxidants may improve sperm parameters and increase fertility outcomes, although results vary depending on dosage, duration, and individual health conditions. Despite promising findings, there are inconsistencies across study methodologies and a lack of standardized treatment protocols, which underscore the need for more rigorous clinical trials. Antioxidant supplementation has the potential to serve as a supportive treatment for male infertility, but it should be approached cautiously and appropriately by carefully selecting patients who are deficient in the administered antioxidants. There is a need to better evaluate the long-term impact on reproductive outcomes and determine the optimal supplementation strategies and patient profiles that would benefit most from supplementation regimens.
- 19 August 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (8) , 1013
Top Cited PapersOpen AccessThe Role of Antioxidants in Male Fertility: A Comprehensive Review of Mechanisms and Clinical Applications
Oxidative stress is a significant factor in male infertility, with increasing evidence evaluating the role of antioxidants in mitigating its detrimental effects on sperm function and quality. This review examines the mechanisms by which reactive oxygen species (ROS) impact male reproductive health. This article synthesizes the different mechanisms at play and highlights key clinical studies published in the literature that contribute to our understanding of antioxidants to treat male infertility. These studies suggest that supplementation with specific antioxidants may improve sperm parameters and increase fertility outcomes, although results vary depending on dosage, duration, and individual health conditions. Despite promising findings, there are inconsistencies across study methodologies and a lack of standardized treatment protocols, which underscore the need for more rigorous clinical trials. Antioxidant supplementation has the potential to serve as a supportive treatment for male infertility, but it should be approached cautiously and appropriately by carefully selecting patients who are deficient in the administered antioxidants. There is a need to better evaluate the long-term impact on reproductive outcomes and determine the optimal supplementation strategies and patient profiles that would benefit most from supplementation regimens.
- 9 November 2023
- Published by Springer Nature
- p. 1185-1208
(Neo) Vaginoplasty in Female Pelvic Congenital Anomalies
- 9 November 2023
- Published by Springer Nature
- p. 1185-1208
(Neo) Vaginoplasty in Female Pelvic Congenital Anomalies
- 1 June 2023
- Published by Springer Nature
- p. 1-24
(Neo) Vaginoplasty in Female Pelvic Congenital Anomalies
- 1 June 2023
- Published by Springer Nature
- p. 1-24
(Neo) Vaginoplasty in Female Pelvic Congenital Anomalies
- 1 April 2023
- Published by SAGE Publications in Journal of Endourology
- Vol. 37 (4) , 474-494
Clinical Applications of Machine Learning for Urolithiasis and Benign Prostatic Hyperplasia: A Systematic Review
Introduction: Previous systematic reviews related to machine learning (ML) in urology often overlooked the literature related to endourology. Therefore, we aim to conduct a more focused systematic review examining the use of ML algorithms for the management of benign prostatic hyperplasia (BPH) or urolithiasis. In addition, we are the first group to evaluate these articles using the Standardized Reporting of Machine Learning Applications in Urology (STREAM-URO) framework. Methods: Searches of MEDLINE, Embase, and the Cochrane CENTRAL databases were conducted from inception through July 12, 2021. Keywords included those related to ML, endourology, urolithiasis, and BPH. Two reviewers screened the citations that were eligible for title, abstract, and full-text screening, with conflicts resolved by a third reviewer. Two reviewers extracted information from the studies, with discrepancies resolved by a third reviewer. The data collected were then qualitatively synthesized by consensus. Two reviewers evaluated each article according to the STREAM-URO checklist with discrepancies resolved by a third reviewer. Results: After identifying 459 unique citations, 63 articles were retained for data extraction. Most articles consisted of tabular ( n = 32) and computer vision ( n = 23) tasks. The two most common problem types were classification ( n = 40) and regression ( n = 12). In general, most studies utilized neural networks as their ML algorithm ( n = 36). Among the 63 studies retrieved, 58 were related to urolithiasis and 5 focused on BPH. The urolithiasis studies were designed for outcome prediction ( n = 20), stone classification ( n = 18), diagnostics ( n = 17), and therapeutics ( n = 3). The BPH studies were designed for outcome prediction ( n = 2), diagnostics ( n = 2), and therapeutics ( n = 1). On average, the urolithiasis and BPH articles met 13.8 (standard deviation 2.6), and 13.4 (4.1) of the 26 STREAM-URO framework criteria, respectively. Conclusions: The majority of the retrieved studies effectively helped with outcome prediction, diagnostics, and therapeutics for both urolithiasis and BPH. While ML shows great promise in improving patient care, it is important to adhere to the recently developed STREAM-URO framework to ensure the development of high-quality ML studies.
- 1 April 2023
- Published by SAGE Publications in Journal of Endourology
- Vol. 37 (4) , 474-494
Clinical Applications of Machine Learning for Urolithiasis and Benign Prostatic Hyperplasia: A Systematic Review
Introduction: Previous systematic reviews related to machine learning (ML) in urology often overlooked the literature related to endourology. Therefore, we aim to conduct a more focused systematic review examining the use of ML algorithms for the management of benign prostatic hyperplasia (BPH) or urolithiasis. In addition, we are the first group to evaluate these articles using the Standardized Reporting of Machine Learning Applications in Urology (STREAM-URO) framework. Methods: Searches of MEDLINE, Embase, and the Cochrane CENTRAL databases were conducted from inception through July 12, 2021. Keywords included those related to ML, endourology, urolithiasis, and BPH. Two reviewers screened the citations that were eligible for title, abstract, and full-text screening, with conflicts resolved by a third reviewer. Two reviewers extracted information from the studies, with discrepancies resolved by a third reviewer. The data collected were then qualitatively synthesized by consensus. Two reviewers evaluated each article according to the STREAM-URO checklist with discrepancies resolved by a third reviewer. Results: After identifying 459 unique citations, 63 articles were retained for data extraction. Most articles consisted of tabular ( n = 32) and computer vision ( n = 23) tasks. The two most common problem types were classification ( n = 40) and regression ( n = 12). In general, most studies utilized neural networks as their ML algorithm ( n = 36). Among the 63 studies retrieved, 58 were related to urolithiasis and 5 focused on BPH. The urolithiasis studies were designed for outcome prediction ( n = 20), stone classification ( n = 18), diagnostics ( n = 17), and therapeutics ( n = 3). The BPH studies were designed for outcome prediction ( n = 2), diagnostics ( n = 2), and therapeutics ( n = 1). On average, the urolithiasis and BPH articles met 13.8 (standard deviation 2.6), and 13.4 (4.1) of the 26 STREAM-URO framework criteria, respectively. Conclusions: The majority of the retrieved studies effectively helped with outcome prediction, diagnostics, and therapeutics for both urolithiasis and BPH. While ML shows great promise in improving patient care, it is important to adhere to the recently developed STREAM-URO framework to ensure the development of high-quality ML studies.
- 23 February 2023
- Published by Springer Nature in World Journal of Urology
- Vol. 41 (4) , 1133-1140
Safety and efficacy of GreenLight PVP in octogenarians: evaluation of the Global GreenLight Group database
Introduction The present study analyzes the largest international GreenLight database, the Global GreenLight Group (GGG), to evaluate the functional and safety profile of GreenLight photoselective vaporization of the prostate (PVP) in octogenarians. Methods The GGG is a database comprised of patients that underwent GreenLight PVP from 2011 to 2019 performed by 8 experienced urologists at 7 international hospitals. Patients 80 years or older at the time of surgery were categorized as octogenarians. They were compared to a similar group of PVP patients below the age of 80. Results Among 3,648 patients, 586 men were above the age of 80. Compared to patients under the age of 80, octogenarians had larger prostates (76.0 vs 71.9 ml, p = 0.02) and a lower BMI (25.6 vs 26.7, p = 0.045). Operative time was not significantly longer in octogenarians. The improvement in functional outcomes between 80-year-old patients and control patients was not significantly different at one-year follow-up, with the exception of maximum urinary flow (Qmax) that favoured younger patients (10.3 vs 12.6 ml/s, p = 0.02). The odds of transfusion were greater for older patients [OR 8.2 (95% CI 3.6–18.9, p < 0.01)], but they were not at increased risk of hematuria. Octogenarians had higher readmission rates (23.0 vs 11.9%, p < 0.01). Conclusions GreenLight PVP is a safe option in well-selected octogenarians in a cohort of patients treated by surgeons experienced with the technology. The odds of transfusion were higher in patients over 80, but the absolute risk remains low. The 30-day hospital readmission rate was higher in octogenarians.
- 23 February 2023
- Published by Springer Nature in World Journal of Urology
- Vol. 41 (4) , 1133-1140
Safety and efficacy of GreenLight PVP in octogenarians: evaluation of the Global GreenLight Group database
Introduction The present study analyzes the largest international GreenLight database, the Global GreenLight Group (GGG), to evaluate the functional and safety profile of GreenLight photoselective vaporization of the prostate (PVP) in octogenarians. Methods The GGG is a database comprised of patients that underwent GreenLight PVP from 2011 to 2019 performed by 8 experienced urologists at 7 international hospitals. Patients 80 years or older at the time of surgery were categorized as octogenarians. They were compared to a similar group of PVP patients below the age of 80. Results Among 3,648 patients, 586 men were above the age of 80. Compared to patients under the age of 80, octogenarians had larger prostates (76.0 vs 71.9 ml, p = 0.02) and a lower BMI (25.6 vs 26.7, p = 0.045). Operative time was not significantly longer in octogenarians. The improvement in functional outcomes between 80-year-old patients and control patients was not significantly different at one-year follow-up, with the exception of maximum urinary flow (Qmax) that favoured younger patients (10.3 vs 12.6 ml/s, p = 0.02). The odds of transfusion were greater for older patients [OR 8.2 (95% CI 3.6–18.9, p < 0.01)], but they were not at increased risk of hematuria. Octogenarians had higher readmission rates (23.0 vs 11.9%, p < 0.01). Conclusions GreenLight PVP is a safe option in well-selected octogenarians in a cohort of patients treated by surgeons experienced with the technology. The odds of transfusion were higher in patients over 80, but the absolute risk remains low. The 30-day hospital readmission rate was higher in octogenarians.
- 19 December 2022
- Published by Springer Nature in World Journal of Urology
- Vol. 41 (2) , 529-536
Functional outcomes of GreenLight 180-W photoselective vaporization in patients with large (≥ 80 cc) prostates: an analysis of over 3000 men in the Global Greenlight Group (GGG) database
Introduction GreenLight photoselective vaporization of the prostate (PVP) has gained widespread adoption as an option to traditional transurethral resection of the prostate. Prior reports expressed concern with the use of PVP in large prostates. The aim of this study was to investigate the adjusted outcomes of GreenLight PVP in men with large (≥ 80 cc) vs. small prostates (< 80 cc). Methods Data were obtained from the Global Greenlight Group which pools data from 7 high volume centers. Men with established benign prostatic hyperplasia who underwent GreenLight PVP using the XPS-180 W system between 2011 and 2019 were eligible and assigned into two groups based on their prostate size (≥ 80 and < 80 cc). 11 functional and perioperative covariates were collected. Analyses were adjusted for patient age and presence of median lobe. Results 3426 men met the inclusion criteria. 34.6% (n = 1187) of patients had a large prostate size. Baseline age and prostate volume were significantly different between the groups. The magnitude of absolute improvement in unadjusted international prostate symptom score was significantly greater in the large (≥ 80 cc) prostate group at 12 months, with an absolute change of 19.17 points (95% CI 18.46–19.88; p < 0.01). There was also a significant drop in PVR at both 6- (p = 0.007) and 12 months (p = 0.005). There were no significant differences in transfusion (p = 0.42), hematuria (p = 0.80), or 30-day readmission rates (p = 0.28). Conclusions Greenlight PVP is a safe and effective alternative for patients with prostate sizes ≥ 80 cc, with durable outcomes relatively independent from prostate size.
- 19 December 2022
- Published by Springer Nature in World Journal of Urology
- Vol. 41 (2) , 529-536
Functional outcomes of GreenLight 180-W photoselective vaporization in patients with large (≥ 80 cc) prostates: an analysis of over 3000 men in the Global Greenlight Group (GGG) database
Introduction GreenLight photoselective vaporization of the prostate (PVP) has gained widespread adoption as an option to traditional transurethral resection of the prostate. Prior reports expressed concern with the use of PVP in large prostates. The aim of this study was to investigate the adjusted outcomes of GreenLight PVP in men with large (≥ 80 cc) vs. small prostates (< 80 cc). Methods Data were obtained from the Global Greenlight Group which pools data from 7 high volume centers. Men with established benign prostatic hyperplasia who underwent GreenLight PVP using the XPS-180 W system between 2011 and 2019 were eligible and assigned into two groups based on their prostate size (≥ 80 and < 80 cc). 11 functional and perioperative covariates were collected. Analyses were adjusted for patient age and presence of median lobe. Results 3426 men met the inclusion criteria. 34.6% (n = 1187) of patients had a large prostate size. Baseline age and prostate volume were significantly different between the groups. The magnitude of absolute improvement in unadjusted international prostate symptom score was significantly greater in the large (≥ 80 cc) prostate group at 12 months, with an absolute change of 19.17 points (95% CI 18.46–19.88; p < 0.01). There was also a significant drop in PVR at both 6- (p = 0.007) and 12 months (p = 0.005). There were no significant differences in transfusion (p = 0.42), hematuria (p = 0.80), or 30-day readmission rates (p = 0.28). Conclusions Greenlight PVP is a safe and effective alternative for patients with prostate sizes ≥ 80 cc, with durable outcomes relatively independent from prostate size.